In a bid to boost its non-cigarette business, itc bet is investing heavily in technology. The company is leveraging artificial intelligence (AI) and machine learning to sharpen its social listening skills, strengthen distribution network and drive process efficiency. It is also deploying big data analytics to support its business and farmer engagements, itc bet said. Moreover, it is using its digital assets to deliver world-class customer experience and build loyalty.

Cigarette business still remains a cash cow for the company as it contributes to around 80% of the total revenue and profits. The company continues to strengthen its cigarette brands through product innovation and price stability. It has also invested in strengthening its distribution network and expanding presence across the country, itc bet added.

In the FMCG segment, itc https://workinnovationbarcelona.org/ is focusing on high-growth categories like soaps and personal care products. The company has launched new categories and introduced innovations such as itc bet soaps with silver nitrate to fight fungal infections. It has also expanded its e-commerce and logistics capabilities.

The company's e-commerce business is now a $5 billion business and it will continue to grow at a faster pace in the future, itc bet said. The company has a large addressable market and is focusing on building a future-ready portfolio.

The non-cigarette business is delivering strong growth and a robust EBITDA margin, itc bet added. The company's FMCG business has grown at over 20% in the past year, itc bet said. Its non-cigarette business currently contributes to 67% of the company's revenues and 28% of its segment EBITDA.

The BET family of proteins bind chromatin through tandem bromodomains (BD1 and BD2) that independently recognize histone tails that have been acetylated on lysine residues. The phylogenetic tree shown in Fig 1a indicates that the BD1 and BD2 of CaBdf1 are conserved between human and fungal species and can therefore be expected to bind multi-acetylated histone peptides. To test this, we designed a series of novel compounds that specifically target CaBdf1 BD1 and BD2 and evaluated binding to a histone tail peptide microarray. The resulting TR-FRET competitive binding data (Fig 1b) show that CaBdf1 BD1 and